{"id":409361,"date":"2021-01-06T08:03:25","date_gmt":"2021-01-06T13:03:25","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=409361"},"modified":"2021-01-06T08:03:25","modified_gmt":"2021-01-06T13:03:25","slug":"replimune-to-present-at-the-39th-annual-j-p-morgan-healthcare-conference","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/replimune-to-present-at-the-39th-annual-j-p-morgan-healthcare-conference\/","title":{"rendered":"Replimune to Present at the 39th Annual J.P. Morgan Healthcare Conference"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"left\">WOBURN, Mass., Jan.  06, 2021  (GLOBE NEWSWIRE) &#8212; Replimune Group, Inc. (NASDAQ: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic\u2122 platform, today announced that Philip Astley-Sparke, Chief Executive Officer of Replimune, will present at the 39th Annual J.P. Morgan Healthcare Conference being held virtually on Tuesday, January 12, 2021 at 5:20 PM ET.<\/p>\n<p>A simultaneous webcast will be available in the Investors section of Replimune\u2019s website at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=gv0pQL0M_zUgCvDRhN_0yrkPgPcR7_o9i3zqBOogt6MK-1982fNacHawhaz08Cpr4ZzENZUsmSu3Q1_drSueGA==\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">www.replimune.com<\/a>. A replay will be available for 30 days following the conference.<\/p>\n<p>\n        <strong>About Replimune <\/strong><br \/>\n        <br \/>Replimune Group, Inc., headquartered in Woburn, MA, was founded in 2015 to develop the next generation of oncolytic immune-gene therapies for the treatment of cancer. Replimune is developing novel, proprietary therapeutics intended to improve the direct cancer-killing effects of selective virus replication and the potency of the immune response to the tumor antigens released. Replimune\u2019s Immulytic\u2122 platform is designed to maximize systemic immune activation, in particular to tumor neoantigens, through robust viral-mediated immunogenic tumor cell killing and the delivery of optimal combinations of immune-activating proteins to the tumor and draining lymph nodes. The approach is expected to be highly synergistic with immune checkpoint blockade and other approaches to cancer treatment across a broad range of cancers. Replimune intends to progress these therapies rapidly through clinical development in combination with other immuno-oncology products with complementary mechanisms of action.\u00a0For more information, please visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=gv0pQL0M_zUgCvDRhN_0ygv3koeQXJqjnLCRgMDFxI5cB1iQ8zncDphvduqw3avO-5kj5hnmKl9eOZdXfSfJGw==\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">www.replimune.com<\/a>.<\/p>\n<p>\n        <strong>Investor Inquiries <\/strong><br \/>\n        <br \/>Chris Brinzey<br \/>Westwicke Partners<br \/>339.970.2843<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=NvjCOeYmL0pTHzmI4rtWVbAqEzTg6iWMa8Vl-f1Rzm3KpGxNorEkA-W6AAVovhK4RCs4k_wzuOgsOzP7LcvasO04PxaDmVkkMgiJkxrOwlvwz_Bg6rvzujuOZQcV_CjP\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">chris.brinzey@westwicke.com<\/a><\/p>\n<p>\n        <strong>Media Inquiries<\/strong><br \/>\n        <br \/>Arleen Goldenberg <br \/>Verge Scientific Communications<br \/>917.548.1582<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=-X_anxQ1-TTEACVV1TgK0hCTR_inNjaI8FBNKPYGDinpJR1nFZvPaEX7tALprmv7R5Zaq2TAX8Ew8JyPNbGKXCfhk6jirQTvufIgFAeLHTdHe9Ry5Vn3FEIpGWzFwF3P\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">agoldenberg@vergescientific.com<\/a><\/p>\n<\/p>\n<p>      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEyMTI1OCMzOTA2MTA0IzIxMTA1MzA=\" width=\"1\" height=\"1\" \/><br \/>\n      <br \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/ml.globenewswire.com\/release\/track\/be14a76a-134f-4bdc-85fc-47acd0c4bbf9\" width=\"1\" height=\"1\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>WOBURN, Mass., Jan. 06, 2021 (GLOBE NEWSWIRE) &#8212; Replimune Group, Inc. (NASDAQ: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic\u2122 platform, today announced that Philip Astley-Sparke, Chief Executive Officer of Replimune, will present at the 39th Annual J.P. Morgan Healthcare Conference being held virtually on Tuesday, January 12, 2021 at 5:20 PM ET. A simultaneous webcast will be available in the Investors section of Replimune\u2019s website at www.replimune.com. A replay will be available for 30 days following the conference. About Replimune Replimune Group, Inc., headquartered in Woburn, MA, was founded in 2015 to develop the next generation of oncolytic immune-gene therapies for the treatment of cancer. Replimune is developing novel, proprietary therapeutics intended to improve the &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/replimune-to-present-at-the-39th-annual-j-p-morgan-healthcare-conference\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Replimune to Present at the 39th Annual J.P. Morgan Healthcare Conference&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-409361","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Replimune to Present at the 39th Annual J.P. Morgan Healthcare Conference - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/replimune-to-present-at-the-39th-annual-j-p-morgan-healthcare-conference\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Replimune to Present at the 39th Annual J.P. Morgan Healthcare Conference - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"WOBURN, Mass., Jan. 06, 2021 (GLOBE NEWSWIRE) &#8212; Replimune Group, Inc. (NASDAQ: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic\u2122 platform, today announced that Philip Astley-Sparke, Chief Executive Officer of Replimune, will present at the 39th Annual J.P. Morgan Healthcare Conference being held virtually on Tuesday, January 12, 2021 at 5:20 PM ET. A simultaneous webcast will be available in the Investors section of Replimune\u2019s website at www.replimune.com. A replay will be available for 30 days following the conference. About Replimune Replimune Group, Inc., headquartered in Woburn, MA, was founded in 2015 to develop the next generation of oncolytic immune-gene therapies for the treatment of cancer. Replimune is developing novel, proprietary therapeutics intended to improve the &hellip; Continue reading &quot;Replimune to Present at the 39th Annual J.P. Morgan Healthcare Conference&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/replimune-to-present-at-the-39th-annual-j-p-morgan-healthcare-conference\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-01-06T13:03:25+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEyMTI1OCMzOTA2MTA0IzIxMTA1MzA=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/replimune-to-present-at-the-39th-annual-j-p-morgan-healthcare-conference\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/replimune-to-present-at-the-39th-annual-j-p-morgan-healthcare-conference\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Replimune to Present at the 39th Annual J.P. Morgan Healthcare Conference\",\"datePublished\":\"2021-01-06T13:03:25+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/replimune-to-present-at-the-39th-annual-j-p-morgan-healthcare-conference\\\/\"},\"wordCount\":259,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/replimune-to-present-at-the-39th-annual-j-p-morgan-healthcare-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODEyMTI1OCMzOTA2MTA0IzIxMTA1MzA=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/replimune-to-present-at-the-39th-annual-j-p-morgan-healthcare-conference\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/replimune-to-present-at-the-39th-annual-j-p-morgan-healthcare-conference\\\/\",\"name\":\"Replimune to Present at the 39th Annual J.P. Morgan Healthcare Conference - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/replimune-to-present-at-the-39th-annual-j-p-morgan-healthcare-conference\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/replimune-to-present-at-the-39th-annual-j-p-morgan-healthcare-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODEyMTI1OCMzOTA2MTA0IzIxMTA1MzA=\",\"datePublished\":\"2021-01-06T13:03:25+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/replimune-to-present-at-the-39th-annual-j-p-morgan-healthcare-conference\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/replimune-to-present-at-the-39th-annual-j-p-morgan-healthcare-conference\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/replimune-to-present-at-the-39th-annual-j-p-morgan-healthcare-conference\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODEyMTI1OCMzOTA2MTA0IzIxMTA1MzA=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODEyMTI1OCMzOTA2MTA0IzIxMTA1MzA=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/replimune-to-present-at-the-39th-annual-j-p-morgan-healthcare-conference\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Replimune to Present at the 39th Annual J.P. Morgan Healthcare Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Replimune to Present at the 39th Annual J.P. Morgan Healthcare Conference - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/replimune-to-present-at-the-39th-annual-j-p-morgan-healthcare-conference\/","og_locale":"en_US","og_type":"article","og_title":"Replimune to Present at the 39th Annual J.P. Morgan Healthcare Conference - Market Newsdesk","og_description":"WOBURN, Mass., Jan. 06, 2021 (GLOBE NEWSWIRE) &#8212; Replimune Group, Inc. (NASDAQ: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic\u2122 platform, today announced that Philip Astley-Sparke, Chief Executive Officer of Replimune, will present at the 39th Annual J.P. Morgan Healthcare Conference being held virtually on Tuesday, January 12, 2021 at 5:20 PM ET. A simultaneous webcast will be available in the Investors section of Replimune\u2019s website at www.replimune.com. A replay will be available for 30 days following the conference. About Replimune Replimune Group, Inc., headquartered in Woburn, MA, was founded in 2015 to develop the next generation of oncolytic immune-gene therapies for the treatment of cancer. Replimune is developing novel, proprietary therapeutics intended to improve the &hellip; Continue reading \"Replimune to Present at the 39th Annual J.P. Morgan Healthcare Conference\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/replimune-to-present-at-the-39th-annual-j-p-morgan-healthcare-conference\/","og_site_name":"Market Newsdesk","article_published_time":"2021-01-06T13:03:25+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEyMTI1OCMzOTA2MTA0IzIxMTA1MzA=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/replimune-to-present-at-the-39th-annual-j-p-morgan-healthcare-conference\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/replimune-to-present-at-the-39th-annual-j-p-morgan-healthcare-conference\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Replimune to Present at the 39th Annual J.P. Morgan Healthcare Conference","datePublished":"2021-01-06T13:03:25+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/replimune-to-present-at-the-39th-annual-j-p-morgan-healthcare-conference\/"},"wordCount":259,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/replimune-to-present-at-the-39th-annual-j-p-morgan-healthcare-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEyMTI1OCMzOTA2MTA0IzIxMTA1MzA=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/replimune-to-present-at-the-39th-annual-j-p-morgan-healthcare-conference\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/replimune-to-present-at-the-39th-annual-j-p-morgan-healthcare-conference\/","name":"Replimune to Present at the 39th Annual J.P. Morgan Healthcare Conference - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/replimune-to-present-at-the-39th-annual-j-p-morgan-healthcare-conference\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/replimune-to-present-at-the-39th-annual-j-p-morgan-healthcare-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEyMTI1OCMzOTA2MTA0IzIxMTA1MzA=","datePublished":"2021-01-06T13:03:25+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/replimune-to-present-at-the-39th-annual-j-p-morgan-healthcare-conference\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/replimune-to-present-at-the-39th-annual-j-p-morgan-healthcare-conference\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/replimune-to-present-at-the-39th-annual-j-p-morgan-healthcare-conference\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEyMTI1OCMzOTA2MTA0IzIxMTA1MzA=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEyMTI1OCMzOTA2MTA0IzIxMTA1MzA="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/replimune-to-present-at-the-39th-annual-j-p-morgan-healthcare-conference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Replimune to Present at the 39th Annual J.P. Morgan Healthcare Conference"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/409361","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=409361"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/409361\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=409361"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=409361"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=409361"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}